Cancer Early Detection
To beat cancer sooner, we need to detect it sooner. Early detection of cancers relies on the ability to identify cancer in its infancy or in a pre-cancerous state, before the disease has spread and while it is still relatively easy to treat. It can have a profound impact on patient outcome and survival, for instance, for UK patients diagnosed with lung cancer at stage 1, 88% survived the disease for at least one year, however, this drops significantly to just 19% if the cancer is diagnosed in the latter stage 4.
Cancer Early Detection
While early detection and long term survival is improving in the most common cancers such as breast, prostate and ovarian cancers, more work is still needed in other cancer types and specific communities at high risk of developing the cancer. Cancer early detection is essential in particularly aggressive cancers typically diagnosed at late stage such as some hepato-pancreato-biliary cancers, or those prevalent within the community.
Early Detection Research
Levering the support and expertise enabled through the recent International Alliance for Cancer Early Detection (ACED) award, the Cancer Early Detection theme is focused on how to use ctDNA and other predictive methods to identify breast and lung cancer sooner, as well as other cancer types.
Manchester has higher-than-average rates of lung cancer and this local need, combined with the expertise and projects initiated through the NIHR Manchester Biomedical Research Centre and ACED, are enabling community engagement programmes in lung cancer early detection involving sample collection, analysis and follow-up treatment over the coming years.
A major focus of our research aspirations centre around cancer in the real world patient or member of the public. Through community engagement schemes, the Early Detection Team will aim to bring the analyse and detection of cancers closer to the home. In addition, our team are investigating how comorbidities and age affect risk of developing cancer.
Navigation
Cancer Biomarkers
Cancer biomarkers are core to our vision of delivering precision medicine for all.
Digital Cancer Centre
Digital research underpins all our research themes. Discover how we leverage technology, AI and data to improve cancer outcomes.
Experimental Cancer Medicine
To improve patient lives, we need new therapies and treatments and early phase clinical trials to continue to be developed.
Integrative Pathology
Acquisition of patient samples is key to translational research and we have developed an extensive biobanking infrastructure to allow collection at all points of the treatment pathway.
Radiotherapy BioAdaption
Radiotherapy plays a vital role in the treatment of cancer and nearly 50% of people receive some form of radiotherapy at some point during cancer treatment.
Research
Navigate back to the Research homepage.